Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

(2014) Sariah Liu et al.   CANCER TREATMENT REVIEWS

Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer

(2014) Greg Durm et al.   Future Oncology

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response

(2013) Agata Matejuk et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Wnt signaling in triple negative breast cancer is associated with metastasis

(2013) Nandini Dey et al.   BMC CANCER

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

(2013) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

(2013) D W Miles et al.   BRITISH JOURNAL OF CANCER

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer

(2013) G. Bisagni et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

(2013) M. Arjaans et al.   CANCER RESEARCH

Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis

(2013) Sandra Schoors et al.   Cell Metabolism

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

(2013) Alessia Bottos et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations

(2013) E. M. Lindholm et al.   CLINICAL CANCER RESEARCH

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Inherent phenotypic plasticity facilitates progression of head and neck cancer: Endotheliod characteristics enable angiogenesis and invasion

(2013) Meng Tong et al.   EXPERIMENTAL CELL RESEARCH

A clinical experience of single agent bevacizumab in relapsing ovarian cancer

(2013) George Emile et al.   GYNECOLOGIC ONCOLOGY

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy

(2013) Robert M. Wenham et al.   GYNECOLOGIC ONCOLOGY

Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer

(2013) Yuji Ikeda et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

(2013) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

(2013) Rakesh K. Jain   JOURNAL OF CLINICAL ONCOLOGY

Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force

(2013) F. Polet et al.   JOURNAL OF INTERNAL MEDICINE

Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme

(2013) Yasushi Soda et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

89Zr-Bevacizumab PET Imaging in Primary Breast Cancer

(2013) S. B. M. Gaykema et al.   JOURNAL OF NUCLEAR MEDICINE

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

(2013) Istvan Lang et al.   LANCET ONCOLOGY

An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

(2013) Alicia S Chung et al.   NATURE MEDICINE

Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

(2013) Chih-Hung Hsu et al.   ONCOLOGY

Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma

(2013) Orit Itzhaki et al.   PLoS One

Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Plays a Key Role in Vasculogenic Mimicry Formation, Neovascularization and Tumor Initiation by Glioma Stem-like Cells

(2013) Xiaohong Yao et al.   PLoS One

Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts

(2013) Patrick C. Hermann et al.   PLoS One

Dynamic Quantitative Intravital Imaging of Glioblastoma Progression Reveals a Lack of Correlation between Tumor Growth and Blood Vessel Density

(2013) Clément Ricard et al.   PLoS One

Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner

(2013) Nandini Dey et al.   PLoS One

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

(2013) Robert Königsberg et al.   Radiology and Oncology

Vascular Permeability and Drug Delivery in Cancers

(2013) Sandy Azzi et al.   Frontiers in Oncology

Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma

(2012) Rangaswamy Govindarajan et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report

(2012) A. F. C. Okines et al.   ANNALS OF ONCOLOGY

VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA

(2012) L. K. Martin et al.   ANNALS OF ONCOLOGY

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

(2012) C. F. Verschraegen et al.   ANNALS OF ONCOLOGY

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

(2012) A. Argiris et al.   ANNALS OF ONCOLOGY

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

(2012) M. Agulnik et al.   ANNALS OF ONCOLOGY

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

(2012) G. J. Ossenkoppele et al.   BLOOD

A randomized phase 2 study of temozolomide and bevacizumab ornab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma

(2012) Lisa A. Kottschade et al.   CANCER

Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

(2012) Manon Buijs et al.   CANCER

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

(2012) Darrell White et al.   CANCER

A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer

(2012) Matthew G. Fury et al.   CANCER

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer

(2012) Robert W. Ross et al.   CANCER

Anti-angiogenesis therapy in cancer: Current challenges and future perspectives

(2012) Farbod Shojaei   CANCER LETTERS

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

(2012) Rachel Borson et al.   Clinical Breast Cancer

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

(2012) J. Moroney et al.   CLINICAL CANCER RESEARCH

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

(2012) Edward B. Garon et al.   Clinical Lung Cancer

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

(2012) I. Lang et al.   EUROPEAN JOURNAL OF CANCER

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma

(2012) S.P. Choo et al.   EUROPEAN JOURNAL OF CANCER

Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

(2012) Todd D. Tillmanns et al.   GYNECOLOGIC ONCOLOGY

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

(2012) Thomas Yau et al.   INVESTIGATIONAL NEW DRUGS

HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma

(2012) Tieju Liu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer

(2012) T J Liu et al.   ONCOGENE

Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells

(2012) Christophe J. De Saedeleer et al.   PLoS One

Hypoxia control to normalize pathologic angiogenesis: Potential role for endothelial precursor cells and miRNAs regulation

(2012) Guillaume Collet et al.   VASCULAR PHARMACOLOGY

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Trophoblastic vasculogenic mimicry in gestational choriocarcinoma

(2011) Ie-Ming Shih   MODERN PATHOLOGY

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Concise Review: Contribution of Cancer Stem Cells to Neovascularization

(2011) Yi-Fang Ping et al.   STEM CELLS

Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature

(2011) M. Pohl et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Contribution of cancer stem cells to tumor vasculogenic mimicry

(2011) Xiao-hong Yao et al.   Protein & Cell

Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy

(2010) Amir Abdollahi et al.   DRUG RESISTANCE UPDATES

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

EPCs and pathological angiogenesis: When good cells go bad

(2010) Sergio Li Calzi et al.   MICROVASCULAR RESEARCH

Vascular Endothelial Growth Factor

(2009) Napoleone Ferrara   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients

(2009) John M. Granger et al.   CANCER

Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy

(2009) Giulio Francia et al.   CANCER CELL

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Characterization and Regulation of Bv8 in Human Blood Cells

(2009) C. Zhong et al.   CLINICAL CANCER RESEARCH

Pathways mediating VEGF-independent tumor angiogenesis

(2009) Napoleone Ferrara   CYTOKINE & GROWTH FACTOR REVIEWS

Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly – A Mini-Review

(2009) S. Boehm et al.   GERONTOLOGY

Rapid Clinical Deterioration and Leukemoid Reaction After Treatment of Urothelial Carcinoma of the Bladder: Possible Effect of Granulocyte Colony-Stimulating Factor

(2009) Francisco A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?

(2009) Dan G. Duda et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

(2009) Francesco Torino et al.   Nature Reviews Clinical Oncology

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

(2009) F. Shojaei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

(2009) Yongping Crawford et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies

(2008) Farbod Shojaei et al.   DRUG RESISTANCE UPDATES

Expression of RAC2 in endothelial cells is required for the postnatal neovascular response

(2008) Pradip De et al.   EXPERIMENTAL CELL RESEARCH